[go: up one dir, main page]

CL2019001664A1 - Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. - Google Patents

Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.

Info

Publication number
CL2019001664A1
CL2019001664A1 CL2019001664A CL2019001664A CL2019001664A1 CL 2019001664 A1 CL2019001664 A1 CL 2019001664A1 CL 2019001664 A CL2019001664 A CL 2019001664A CL 2019001664 A CL2019001664 A CL 2019001664A CL 2019001664 A1 CL2019001664 A1 CL 2019001664A1
Authority
CL
Chile
Prior art keywords
methods
heterocyclic compounds
same
substituted heterocyclic
amine substituted
Prior art date
Application number
CL2019001664A
Other languages
English (en)
Inventor
John Emmerson Campbell
Kenneth William Duncan
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CL2019001664A1 publication Critical patent/CL2019001664A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE DIVULGACIÓN SE REFIERE A COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMINA. LA PRESENTE DIVULGACIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN ESTOS COMPUESTOS Y A MÉTODOS PARA TRATAR UN TRASTORNO (P. EJ., CÁNCER) MEDIANTE LA INHIBICIÓN DE UNA ENZIMA METILTRANSFERASA SELECCIONADA DE EHMT1 Y EHMT2, ADMINISTRANDO UN COMPUESTO HETEROCÍCLICO SUSTITUIDO CON AMINA DESCRITO EN LA PRESENTE O UNA COMPOSICIÓN FARMACÉUTICA DE ESTE A SUJETOS QUE LO NECESITEN. LA PRESENTE DIVULGACIÓN TAMBIÉN SE REFIERE AL USO DE TALES COMPUESTOS EN INVESTIGACIÓN U OTROS FINES NO TERAPÉUTICOS.
CL2019001664A 2016-12-19 2019-06-17 Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. CL2019001664A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436139P 2016-12-19 2016-12-19
US201762517840P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
CL2019001664A1 true CL2019001664A1 (es) 2019-12-06

Family

ID=60972416

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019001664A CL2019001664A1 (es) 2016-12-19 2019-06-17 Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
CL2020001133A CL2020001133A1 (es) 2016-12-19 2020-04-29 Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001133A CL2020001133A1 (es) 2016-12-19 2020-04-29 Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664)

Country Status (25)

Country Link
US (2) US20200039998A1 (es)
EP (2) EP3555070B1 (es)
JP (2) JP2020504715A (es)
KR (1) KR102693367B1 (es)
CN (2) CN116041346A (es)
AU (3) AU2017382830A1 (es)
BR (1) BR112019012140A2 (es)
CA (1) CA3045032A1 (es)
CL (2) CL2019001664A1 (es)
CO (1) CO2019006787A2 (es)
DK (1) DK3555070T3 (es)
ES (1) ES2955132T3 (es)
FI (1) FI3555070T3 (es)
HU (1) HUE063405T2 (es)
IL (1) IL267090A (es)
LT (1) LT3555070T (es)
MA (1) MA47233A (es)
MX (1) MX2019007234A (es)
PL (1) PL3555070T3 (es)
PT (1) PT3555070T (es)
SG (1) SG10201913464TA (es)
SI (1) SI3555070T1 (es)
TW (2) TWI808067B (es)
WO (1) WO2018118842A1 (es)
ZA (1) ZA201904234B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
AU2017336074A1 (en) * 2016-09-30 2019-03-28 Epizyme, Inc. Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
BR112019016707A2 (pt) * 2017-02-14 2020-04-07 Effector Therapeutics Inc inibidores de mnk substituídos por piperidina e métodos relacionados aos mesmos
CA3058639A1 (en) * 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CA3069524A1 (en) 2017-07-14 2019-01-17 Innate Tumor Immunity, Inc. Nlrp3 modulators
CA3079260A1 (en) * 2017-10-17 2019-04-25 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof
EP3697400A4 (en) * 2017-10-18 2021-08-11 Epizyme, Inc. METHOD OF USING EHMT2 INHIBITORS TO TREAT OR PREVENT BLOOD DISEASES
US20200247790A1 (en) * 2017-10-18 2020-08-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US11130757B2 (en) 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020150116A1 (en) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Nlrp3 modulators
JP7577672B2 (ja) 2019-02-22 2024-11-05 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
JP2022527279A (ja) * 2019-03-28 2022-06-01 エピザイム，インコーポレイティド キノリン誘導体及び癌の治療のためのその使用
WO2020262974A1 (ko) 2019-06-27 2020-12-30 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN115996917B (zh) 2020-05-06 2025-10-28 艾捷斯治疗公司 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
EP4267565A4 (en) 2020-12-22 2025-01-08 InventisBio Co., Ltd. HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023064586A1 (en) * 2021-10-15 2023-04-20 Tango Therapeutics, Inc. Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物
KR20250040981A (ko) * 2022-07-20 2025-03-25 주식회사 에스투시바이오 헤테로아릴 유도체 화합물 및 이의 용도
CN115974727B (zh) * 2023-01-17 2024-03-12 青岛前线生物工程有限公司 一种联苯肼酯的合成方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
ES2271283T3 (es) * 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
EP1910349A1 (en) * 2005-07-15 2008-04-16 4Sc Ag 2-arylbenzothiazoles and uses thereof
AU2006326989B2 (en) * 2005-12-21 2011-11-24 Novartis Ag Pyrimidinyl aryl urea derivatives being FGF inhibitors
TW200902010A (en) * 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
CA2693594A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
ES2428716T3 (es) * 2008-02-22 2013-11-11 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide
PT2389372E (pt) * 2009-01-23 2016-01-07 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
CN104640863B (zh) * 2012-09-20 2016-06-08 山东亨利医药科技有限责任公司 嘧啶胺衍生物及其制备方法和应用
JP6357167B2 (ja) * 2012-12-04 2018-07-11 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびそれらの用途
US9169249B2 (en) * 2013-03-14 2015-10-27 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2014152768A1 (en) * 2013-03-15 2014-09-25 Portola Pharmaceuticals, Inc. Cyclohexanediamine compounds and methods for their preparation
WO2016175264A1 (ja) * 2015-04-28 2016-11-03 カルナバイオサイエンス株式会社 抗マラリア活性を有する新規ヘテロアリール誘導体
SG10201913471VA (en) * 2016-04-15 2020-03-30 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CN106083828A (zh) * 2016-06-30 2016-11-09 浙江大学 含吖丙啶环侧链的芳胺嘧啶衍生物及制备和应用

Also Published As

Publication number Publication date
ES2955132T3 (es) 2023-11-28
BR112019012140A2 (pt) 2019-11-05
CO2019006787A2 (es) 2019-09-30
CL2020001133A1 (es) 2020-11-06
KR20190092542A (ko) 2019-08-07
KR102693367B1 (ko) 2024-08-12
AU2022202494A1 (en) 2022-05-12
TW202411220A (zh) 2024-03-16
AU2022202494B2 (en) 2024-05-02
EP3555070A1 (en) 2019-10-23
HUE063405T2 (hu) 2024-01-28
EP4285906A2 (en) 2023-12-06
TW201833102A (zh) 2018-09-16
MA47233A (fr) 2019-10-23
SI3555070T1 (sl) 2023-11-30
AU2017382830A1 (en) 2019-06-13
SG10201913464TA (en) 2020-03-30
EP4285906A3 (en) 2024-03-13
CN116041346A (zh) 2023-05-02
TWI808067B (zh) 2023-07-11
CA3045032A1 (en) 2018-06-28
US20220235065A1 (en) 2022-07-28
FI3555070T3 (fi) 2023-09-12
EP3555070B1 (en) 2023-08-09
US20200039998A1 (en) 2020-02-06
WO2018118842A1 (en) 2018-06-28
PT3555070T (pt) 2023-09-14
JP2020504715A (ja) 2020-02-13
CN110088099A (zh) 2019-08-02
CN110088099B (zh) 2023-01-31
IL267090A (en) 2019-08-29
LT3555070T (lt) 2023-09-11
PL3555070T3 (pl) 2023-11-06
DK3555070T3 (da) 2023-09-18
AU2024205290A1 (en) 2024-08-22
JP2022110080A (ja) 2022-07-28
ZA201904234B (en) 2025-09-25
MX2019007234A (es) 2019-09-06

Similar Documents

Publication Publication Date Title
CL2019001664A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
CR20170484A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CL2016001232A1 (es) Inhibidores tetracíclicos de autotaxina
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
MX380401B (es) Compuestos de benzamida y nicotinamida y metodos para usar los mismos.
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores